Oncolytic Adenovirus H101 With Nivolumab for Refractory Advanced Hepatocellular Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study
ESMO Open 2024 Feb 01;9(2)102239, L Yi, Z Ning, L Xu, Y Shen, X Zhu, W Yu, J Xie, Z MengFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.